Your browser does not support SVG.
HOME
PIPELINE
LEADERSHIP
Management Team
Board of Directors
DISEASES
Acne vulgaris
Atopic dermatitis
Hyperhidrosis
Psoriasis
Vitiligo
NEWS
CAREERS
CONTACT
RVT-502
RVT-502
December 3, 2019
Dermavant Announces First Patient Dosed in Phase 2 ...
Read More
December 6, 2018
Dermavant Sciences to Present New Data on Cerdulat ...
Read More
Recent Posts
Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream for the Treatment of Atopic Dermatitis
Dermavant Completes Patient Enrollment for Long-Term Safety Study of Tapinarof in Adult Patients with Psoriasis
Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream for the Treatment of Plaque Psoriasis
Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis
Dermavant Appoints Chris Chapman as Chief Commercial Officer
Archives
June 2020
May 2020
April 2020
January 2020
December 2019
June 2019
May 2019
March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
April 2018
September 2017
July 2017
December 2016
November 2015
Categories
Dermavant Sciences
News
RVT-201
RVT-501
RVT-502
RVT-504
Tapinarof
